Opinion

Video

Examining Safety and Efficacy of BTK Inhibitors In CLL and SLL Treatment

Safety considerations for BTKi use in CLL and SLL treatment are highlighted.

This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; and Jennifer Woyach, MD.

The group discusses the lack of head-to-head trials comparing the next-generation Bruton tyrosine kinase (BTK) inhibitors acalabrutinib and zanubrutinib. Currently, the only comparative data come from trials in the relapsed/refractory setting. The ELEVATE-RR trial compared acalabrutinib withibrutinib and the ALPINE trial compared zanubrutinibwithibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL). These trials showed improved safety profiles with the next-generation BTK inhibitors, but they enrolled slightly different patient populations.

Without head-to-head data, providers must extrapolate the improved safety seen with next-generation BTK inhibitors in the relapsed setting into the frontline setting. Real-world evidence and matched-adjusted indirect comparisons can provide additional data but have limitations. Ultimately, providers may choose based on personal experience and subtle differences in adverseeffect profiles to best match the treatment to an individual patient. Having multiple next-generation options allows switching between covalent BTK inhibitors if a patient experiences intolerable adverseeffects while maintaining efficacy.

The National Comprehensive Cancer Network guidelines now list acalabrutinib and zanubrutinib as preferred frontline BTK inhibitor options over ibrutinib. More comparative data arestill needed, but the next-generation BTK inhibitors have established themselves as safer options than ibrutinib.

 

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
1 expert is featured in this series.
5 experts are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo